Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 180,700 shares, a decrease of 22.5% from the October 31st total of 233,300 shares. Currently, 0.9% of the company’s stock are sold short. Based on an average trading volume of 78,900 shares, the days-to-cover ratio is currently 2.3 days.

Aileron Therapeutics Trading Up 4.4 %

NASDAQ:ALRN traded up $0.12 during mid-day trading on Friday, hitting $2.86. 14,804 shares of the company’s stock traded hands, compared to its average volume of 73,709. The firm has a 50 day moving average of $3.46 and a two-hundred day moving average of $3.07. The firm has a market capitalization of $61.98 million, a price-to-earnings ratio of -0.88 and a beta of 2.35. Aileron Therapeutics has a 12 month low of $1.61 and a 12 month high of $7.42.

Institutional Investors Weigh In On Aileron Therapeutics

Several large investors have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. bought a new stake in Aileron Therapeutics during the second quarter worth about $4,925,000. Nantahala Capital Management LLC boosted its holdings in shares of Aileron Therapeutics by 82.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after acquiring an additional 209,367 shares in the last quarter. Geode Capital Management LLC grew its position in Aileron Therapeutics by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after acquiring an additional 59,370 shares during the last quarter. Sigma Planning Corp increased its holdings in Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after purchasing an additional 86,185 shares in the last quarter. Finally, Warberg Asset Management LLC bought a new position in Aileron Therapeutics in the 2nd quarter valued at $86,000. 90.89% of the stock is currently owned by institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).